Q&A with A&V Livestream 3/23/22
Virologists Amy Rosenfeld and Vincent Racaniello answer your COVID-19 questions (or any virus questions) on this livestream of 3/23/22 at 8:30 PM eastern US.
Virologists Amy Rosenfeld and Vincent Racaniello answer your COVID-19 questions (or any virus questions) on this livestream of 3/23/22 at 8:30 PM eastern US.
In COVID-19 clinical update #106, Daniel Griffin covers failure of ivermectin to improve hospitalization, increased hospitalization of children with Omicron, seroconversion of children versus adults, effectiveness of Pfizer mRNA vaccine in children, high vaccine effectiveness in Finland against Omicron, distinct long COVID clinical phenotypes, and estimating worldwide excess mortality.
In COVID-19 clinical update #105, Daniel Griffin discusses changes in brain structure after infection, dementia in patients with pneumonia, Paxlovid in children, mask effectiveness in schools, host factors and severe disease, post-acute symptoms, and the mission of CEPI. Click arrow to playDownload TWiV 874 (49 MB .mp3, 41 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Show notes …
TWiV 874: COVID-19 clinical update #105 with Dr. Daniel Griffin Read More »
In COVID-19 clinical update #104, Daniel Griffin reviews effectiveness of mRNA vaccines among children, number of children affected by disease, accuracy of rapid antigen tests, CDC guidance for prevention strategies, monoclonal antibody effectiveness, predicting progression to severe respiratory failure from pneumonia, risk of long COVID after two vaccine doses, and peripheral neuropathy in long COVID.
By David Tuller, DrPH In what could be described as a form of epistemic land grab, core members of the graded exercise therapy/cognitive behavior therapy (GET/CBT) ideological brigades have proposed a “research agenda” for long Covid that reflects the premises of their crumbling treatment paradigm for ME/CFS. This is not surprising. It has been clear …
TWiV discusses whether or not Omicron should be designated a new serotype of SARS-CoV-2, and the finding that amino acid changes that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway.